Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China

Xingxian Luo(Peking University), Yang Yue(China Academy of Urban Planning and Design), Qixiang Guo(National Medical Products Administration), Lin Huang(Sun Yat-sen University), Xuecai Xue(Peking University), Kaidi Le(Chinese Academy of Medical Sciences & Peking Union Medical College), Xufeng Lv(National Medical Products Administration), Haoran Li(Harbin Institute of Technology), Jingwen Liu(National Medical Products Administration), Xiaomeng Jiang(National Medical Products Administration), Xin Du(Shandong Normal University), Cen Wang(Hong Kong University of Science and Technology), Zhuangqi Li(National Medical Products Administration)
JAMA Network Open
October 12, 2023
Cited by 15


Related Papers